AbbVie acquired Aliada Therapeutics Holdings, Inc. for $1.4 billion upfront, a transaction completed in December 2024, structured as all cash (asset acquisition).
Aliada Therapeutics Holdings, Inc. operates in Neuroscience (CNS). Aliada is advancing therapies using a novel blood-brain-barrier-crossing technology to address central nervous system diseases. Its lead asset, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Abeta) antibody in development for Alzheimer's disease. AbbVie paid approximately $1.4 billion upfront and accounted for the transaction as an asset acquisition.
Adds a differentiated blood-brain-barrier platform and an Alzheimer's asset to AbbVie's neuroscience pipeline.
Advisory firms were not disclosed for this transaction.